A Preoperative "Window-opportunity", Multicenter, Pharmacokinetic-pharmacodynamic Study to Evaluate the Inhibitory Effects of Single Agent AZD2281 (Olaparib), in Patients With Early-stage Endometrial Carcinoma

Trial Profile

A Preoperative "Window-opportunity", Multicenter, Pharmacokinetic-pharmacodynamic Study to Evaluate the Inhibitory Effects of Single Agent AZD2281 (Olaparib), in Patients With Early-stage Endometrial Carcinoma

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Olaparib (Primary)
  • Indications Endometrial cancer
  • Focus Pharmacodynamics
  • Acronyms POLEN
  • Most Recent Events

    • 07 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
    • 07 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
    • 29 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top